Constellation Pharmaceuticals Investor Presentation — June 2020

Document content

Stellar Science, Breakthrough Medicine

CPI-0610: Update of Preliminary

Analyst/Investor Meeting on EHA Posters

Forward -Looking Statements

This presentation and discussion contain forward -looking statements within the meaning of The Private Securities Litigation Refo rm Act of

1995 that involve substantial risks and uncertainties, including statements regarding the implications of preliminary or inte rimclinical data,

Company’s plans, strategies and prospects for its business and statements regarding the development status of the Company’s p roduct

candidates. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential ,” “predict,” “project,”

“should,” “target,” “will,” “would” and similar expressions are intended to identify forward -looking statements, although not al l forward -looking

statements contain these identifying words. Any forward -looking statements are based on management’s current expectations of fut ure

events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and advers elyfrom those set

forth in, or implied by, such forward -looking statements. These risks and uncertainties include, but are not limited to, risks a ssociated with the

Company’s ability to: obtain and maintain necessary approvals from the FDA and other regulatory authorities; continue to adva nceits product

candidates in clinical trials; whether preliminary or interim data from a clinical trial will be predictive of the final resu ltsof the trial; replicate in

later clinical trials positive results found in preclinical studies and early -stage clinical trials of CPI -0610, CPI -1205 and CP I-0209; advance the

development of its product candidates under the timelines it anticipates, or at all, in current and future clinical trials; o btain, maintain, or

protect intellectual property rights related to its product candidates; manage expenses; raise the substantial additional cap ital needed to

achieve its business objectives; the COVID -19 pandemic and general economic and market conditions. CPI -0610, CPI -1205 and CPI -0209

are investigational therapies and have not been approved by the FDA (or any other regulatory authority). For a discussion of other risks and

uncertainties, any of which could cause the Company’s actual results to differ from those contained in the forward -looking state ments, see the

“Risk Factors” section, as well as discussions of potential risks, uncertainties, and other important factors, in the Company ’s most recent

filings with the Securities and Exchange Commission, including the Company’s Quarterly Report on Form 10 -Q for the quarter ended March